Respirology Search
Respirology Respirology
influenza
INFLUENZA
The clinical spectrum of influenza ranges from asymptomatic infection to primary viral pneumonia that may progress to death.
Patients presenting with influenza-like illness (ie temperature of 37.8ºC, cough and/or sore throat and absence of a known cause other than influenza) might be infected with different types of influenza virus [eg avian influenza (H5N1)] as well as other respiratory pathogens.
A high index of suspicion is needed to recognize influenza in hospitalized patients.
Pneumonia is the most common complication of influenza virus.

Influenza Drug Information

Drug Information

Indication: Relief of mild to moderate pain & fever.

Indication: Prevention of influenza disease caused by influenza types A & B viruses.

Indication: Active immunisation of adults & childn ≥6 mth for prevention of influenza disease caused by 2 influenza...

Indication: Relief of symptoms associated w/ allergic rhinitis & common cold including nasal congestion, sneezing, rhi...

Indication: Relief of symptoms associated w/ allergic rhinitis & common cold including nasal congestion, sneezing, rhi...

Indication: Prevention of flu in persons ≥65 yr; adults & childn w/ chronic pulmonary & CV disorders, chronic m...

Actimol Menstrual
pamabrom + paracetamol

Indication: Symptomatic relief of bloating, water-wt gain, backache, muscular aches, pre-menstrual & menstrual discomf...

Alka-Seltzer
aspirin + citric acid + sodium bicarbonate

Indication: Relief of headache & upset stomach. Fever, colds & flu discomfort, muscular aches & pains.

Indication: Mild to moderate pain & fever.

Indication: Reduction of sputum viscosity.

1  /  15
1  /  15
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Ivermectin improves survival in COVID-19 patients with severe pulmonary involvement
21 Nov 2020
Ivermectin confers benefits in the treatment of COVID-19, with a recent study showing that its use helps reduce the risk of death especially in patients with severe pulmonary involvement.
COVID-19: Are we close to a cure?
Elvira Manzano, 12 May 2020
After months of work disruption, profound worrying, social distancing, and isolation, SARS-CoV-2* still rages on, unyielding to human interventions.
Searches for unproven COVID-19 therapies spike after high-profile endorsements
Roshini Claire Anthony, 18 Jun 2020

Endorsement of unproven COVID-19 treatments by high-profile public figures led to a drastic increase in the search and purchase of said treatments in the US, according to a research letter published in JAMA.
Gut dysbiosis in COVID-19 prompts development of probiotic supplement
Christina Lau, 23 Jun 2020

Patients with coronavirus disease 2019 (COVID-19) have significant gut dysbiosis that persists even after viral clearance and resolution of respiratory symptoms, according to a metagenomic study by the Chinese University of Hong Kong (CUHK). These findings have led to the development of a probiotic supplement expected to be available in a few months.